Clinical Trial Update: An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 efficacy study results comparing ipilimumab to the standard of care after first-line chemotherapy in locally advanced unresectable or metastatic gastric…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Ipilimumab (Yervoy) (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction | Phase 2 | Status: COMPLETED | Results posted: 2015-11-18